🔓
Sign in as a Member to unlock the full view of KNSA. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
KNSA

Kiniksa Pharmaceuticals, Ltd.

Sector: healthcareBiotechnologyNASDAQMarket Cap: $3.50B

Kiniksa is a small-cap biopharmaceutical company with minimal political engagement and no material government dependence, focused on rare inflammatory diseases.

Next filing → your inbox
Govt Dependence
15/100
Regulatory Density
75/100
Lobbying Intensity
5/100
Political Signal
LOW

BusinessWhat KNSA does

Kiniksa develops and commercializes therapies for rare inflammatory conditions, including autoinflammatory diseases and other specialty indications. Revenue derives primarily from product sales of approved therapies; the company has minimal government contract revenue and operates in the specialty pharma segment.

Lifetime Government AwardsKNSA federal contracts

KNSA doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding KNSA

$154.8M
Total KNSA held by tracked 13F funds
6
Funds with KNSA positions
Point72 Asset Management $42M holds 2026-06-30
D.E. Shaw & Co. $36M -41% 2026-06-30
Two Sigma Investments $36M +33% 2026-06-30
AQR Capital Management $24M holds 2026-06-30
Renaissance Technologies $12M +143% 2026-09-30
Citadel Advisors $4M -88% 2026-06-30

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

1
stock awards · $9K market value
52
option exercises · $10.9M
2026-07-15 Megna Michael R CHIEF ACCOUNTING OFFICER AWARD 279 sh $9K
For KNSA, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills to WatchLegislation flagged by our analysis

Inflation Reduction Act drug pricing provisionsPDUFA reauthorizationorphan drug incentive reforms

Political ProfileWhere KNSA sits in Washington

Kiniksa has no measurable political trading activity, minimal lobbying footprint, and no named legislative winners/losers. Stock movement driven primarily by clinical trial results and FDA decisions rather than political events.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • FDA approval delays
  • Medicare pricing pressure
  • drug pricing legislation

Regulatory opportunities

  • orphan drug exclusivity extension
  • accelerated approval pathways
  • rare disease tax credits
Member intelligence layer

Live signals + predictions for KNSA — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout KNSA & political exposure

Does Kiniksa Pharmaceuticals, Ltd. (KNSA) hold federal contracts?
No direct prime contracts reported in USASpending.gov for Kiniksa Pharmaceuticals, Ltd.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
What is KNSA political risk profile?
Government dependence: 15/100. Lobbying intensity: 5/100. Political signal: low.
How does GovGreed track KNSA political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. KNSA data is updated daily from these official federal sources.